Novo Nordisk A/ S stock (DK0060534915): weight-loss boom meets fresh earnings update

Novo Nordisk A/S remains in the spotlight as the maker of blockbuster diabetes and obesity drugs continues to post strong earnings and expand capacity for Wegovy and Ozempic. US investors watch how new guidance, pricing dynamics and competition might shape the next phase of growth.

Novo Nordisk A/S stays at the center of global market attention as demand for its GLP-1 diabetes and obesity medicines drives double?digit growth and fresh records in revenue and profit. In its most recent quarterly report for the first quarter of 2025, the Danish drug maker reported sharply higher sales led by Ozempic and Wegovy and raised its full?year outlook, according to the company’s earnings release published on 05/02/2025.Novo Nordisk Q1 2025 report as of 05/02/2025

On the back of these results, Novo Nordisk shares continued to trade near all?time highs on the Copenhagen exchange and in US trading via American depositary receipts. The stock was quoted around 1,255 DKK on 05/05/2025 on Nasdaq Copenhagen, while the US?listed ADR NVO hovered near 140 USD on 05/05/2025 on the New York Stock Exchange, according to market data reported by Reuters as of 05/05/2025.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk
• Sector/industry: Pharmaceuticals / biopharma (diabetes and obesity)
• Headquarters/country: Bagsværd, Denmark
• Core markets: North America, Europe and selected international markets
• Key revenue drivers: GLP?1 diabetes and obesity drugs such as Ozempic and Wegovy
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NOVO-B), US ADR on NYSE (ticker: NVO)
• Trading currency: Danish krone in Copenhagen, US dollar for ADR

Novo Nordisk A/S: core business model

Novo Nordisk is focused on chronic diseases, with a historical emphasis on diabetes care. The company’s business model centers on discovering, developing, manufacturing and marketing injectable and oral therapies that support long?term disease management for millions of patients worldwide. Over the past decade, it has systematically shifted its portfolio toward next?generation treatments with higher clinical value and stronger intellectual?property protection.

The backbone of Novo Nordisk’s model is its leadership in insulin and GLP?1 analog therapies. Insulin products still represent an important base, particularly in emerging markets, but the faster?growing segment is GLP?1 treatments for type 2 diabetes and obesity. These medicines command premium pricing thanks to demonstrated efficacy in blood?sugar control and, increasingly, weight loss, cardiovascular outcomes and other metabolic benefits, according to the company’s 2024 annual report published on 01/31/2025.Novo Nordisk annual report 2024 as of 01/31/2025

The group operates with a high degree of vertical integration. It runs its own R&D centers, large?scale biologics manufacturing plants and a global commercial organization. This structure is capital?intensive but allows for tight control over supply, quality and margins. Capacity expansion has become a key strategic priority because demand for GLP?1 drugs is growing faster than initial expectations. In 2023 and 2024 the company announced multi?billion?dollar investments in new production sites in Denmark and the United States, according to company press releases dated 11/09/2023 and 06/24/2024.Novo Nordisk capacity investment update as of 11/09/2023

From a revenue model perspective, Novo Nordisk generates cash primarily from drug sales reimbursed by public health systems and private insurers. Pricing negotiations and rebate structures are central, particularly in the United States where pharmacy benefit managers and Medicare rules play a decisive role. Despite discount pressure, the high clinical value of GLP?1 drugs has allowed the company to maintain attractive net prices in key indications, especially obesity and type 2 diabetes. This dynamic underpins the group’s robust operating margin profile, which exceeded 40% in 2024, according to the 2024 annual report published on 01/31/2025.Novo Nordisk annual report 2024 as of 01/31/2025

Main revenue and product drivers for Novo Nordisk A/S

The central revenue engine at Novo Nordisk is its GLP?1 franchise, particularly Ozempic for type 2 diabetes and Wegovy for chronic weight management. In the first quarter of 2025, GLP?1 diabetes and obesity care revenues rose sharply and accounted for the majority of group sales, according to the Q1 2025 interim report released on 05/02/2025.Novo Nordisk Q1 2025 report as of 05/02/2025

Ozempic, a once?weekly injectable semaglutide for type 2 diabetes, remains the flagship product. It has demonstrated strong blood?glucose control and weight?loss benefits, leading to broad uptake in both the US and Europe. Wegovy, a higher?dose semaglutide formulation approved specifically for obesity, has unlocked a rapidly expanding market of patients seeking medical weight management beyond bariatric surgery and lifestyle changes. Regulatory approvals in the US and several European countries have widened the addressable patient base, according to multiple regulatory announcements referenced in Novo Nordisk’s 2024 annual report published on 01/31/2025.Novo Nordisk annual report 2024 as of 01/31/2025

Beyond semaglutide, Novo Nordisk is developing next?generation obesity and cardiometabolic drugs, including CagriSema, a combination of semaglutide and the amylin analog cagrilintide. Late?stage clinical results and regulatory submissions for these pipeline assets are closely watched by investors because they could define the company’s competitive position as rivals like Eli Lilly advance their own multi?agonist therapies. Novo Nordisk highlighted progress in phase 3 programs and additional indications for semaglutide in its R&D update released on 11/05/2024.Novo Nordisk R&D update as of 11/05/2024

Diabetes care beyond GLP?1, including basal insulin products like Tresiba and rapid?acting insulins, continues to provide a stable cash flow base but grows more slowly due to biosimilar competition and pricing pressure. Biopharm products in areas such as rare blood disorders and growth hormone therapy contribute a smaller share of revenue, yet they offer diversification and may benefit from specialized pricing and limited competition. Overall, the revenue mix has shifted markedly toward high?growth obesity and diabetes treatments, which now dominate both top?line growth and profit contribution.

Industry trends and competitive position

Novo Nordisk operates in a biopharmaceutical industry where chronic metabolic diseases are a long?term growth theme. Rising rates of obesity and type 2 diabetes worldwide increase demand for effective treatments. In the United States, obesity prevalence has surpassed 40% in adults, according to data released by the US Centers for Disease Control and Prevention in 2023, creating a large potential pool of patients eligible for pharmacologic weight management.CDC obesity statistics as of 03/01/2023

Novo Nordisk’s main competitor in GLP?1 and obesity treatment is US?based Eli Lilly, which markets tirzepatide under the brand names Mounjaro for diabetes and Zepbound for obesity. Investor focus has shifted toward how these two companies will share the market, expand manufacturing and navigate payer dynamics. While Lilly has taken share in some segments, Novo Nordisk remains deeply entrenched in diabetes care and has built strong relationships with physicians and payers over decades, according to sector coverage by Financial Times as of 10/15/2024.

Supply constraints have been a recurring theme. Both Novo Nordisk and competitors have struggled to meet surging demand, leading to intermittent shortages of certain dose strengths. Novo Nordisk’s ongoing investments in additional manufacturing capacity in Denmark, the US and other locations aim to ease bottlenecks over the coming years. Until then, rationing of supply between geographies and indications may limit the pace at which new patients start therapy, which could influence quarterly growth patterns and short?term revenue volatility.

Why Novo Nordisk A/S matters for US investors

For US investors, Novo Nordisk is relevant on several levels. First, the company’s ADR trades on the New York Stock Exchange under the ticker NVO, providing straightforward access in US brokerage accounts. The firm is a major constituent of global health care and pharmaceutical indices, and its market capitalization places it among the most valuable drug makers in the world, which means it can influence sector?wide ETF performance.

Second, the United States is Novo Nordisk’s largest single market. A substantial portion of sales and profit is generated from US patients treated for diabetes and obesity. As a result, changes in US health policy, drug?pricing regulations and reimbursement decisions can have a direct impact on the company’s financial results. Debates around GLP?1 coverage under Medicare, employer health plans and Medicaid programs are closely watched by investors, as reported by Reuters as of 09/18/2024.

Third, Novo Nordisk’s success in obesity drugs has broader implications for sectors far beyond pharmaceuticals. US market participants track the potential impact of widespread weight?loss drug use on industries ranging from food and beverage to medical devices, airlines and retail, as discussed in sector analysis by Bloomberg as of 01/08/2024. This spillover effect can make Novo Nordisk an important indicator for broader consumer and health?care trends in the US economy.

Risks and open questions

Despite strong fundamentals, Novo Nordisk faces a range of risks that US investors monitor closely. Regulatory risk is significant: future changes in US or European drug?pricing frameworks, rebate rules or safety requirements could alter the profitability of GLP?1 therapies. Political attention has increased as payers grapple with the budget impact of rapidly rising spending on obesity drugs, especially if they become widely used for preventive purposes in large populations.

Competition is another key uncertainty. Eli Lilly and other pharmaceutical companies are advancing their own multi?agonist and next?generation weight?loss drugs, some of which could offer greater efficacy or more convenient administration. If competitors demonstrate better outcomes in cardiovascular risk reduction, renal protection or other endpoints, Novo Nordisk’s market share could come under pressure over time. Additionally, any unexpected safety signal in large real?world populations could lead to label changes, usage restrictions or litigation risk, even though current clinical data support the safety profile described in regulatory documents.

Operationally, the pace at which Novo Nordisk can add manufacturing capacity will influence its ability to sustain growth. Delays or cost overruns in large capital projects could affect margins and limit volume expansion in the near term. Currency fluctuations between the Danish krone, US dollar and other currencies also introduce earnings volatility, as highlighted in the 2024 annual report published on 01/31/2025.Novo Nordisk annual report 2024 as of 01/31/2025

Conclusion

Novo Nordisk A/S has transformed from a traditional insulin specialist into a global leader in obesity and cardiometabolic drugs, with semaglutide?based therapies at the core of its growth story. Recent quarterly earnings and raised guidance underscore how powerful this franchise has become, even as supply constraints and competitive challenges remain. For US investors, the stock offers exposure to one of the most closely watched themes in health care, but performance will depend on how the company manages pricing debates, capacity expansion, pipeline execution and rivalry with other large drug makers. Monitoring regulatory developments, real?world data on GLP?1 use and capital?investment progress will be crucial for assessing the sustainability of Novo Nordisk’s current momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.